Secondary analysis (biomarker substudy) of the COPEC trial in 153 patients with locally advanced rectal cancer on neoadjuvant chemotherapy: high-risk ctDNA dynamics were associated with poor response (59.4% vs 12.4%; OR 11.69).
Secondary analysisn = 153
Shen et al. Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy